安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- The New England Journal of Medicine | Research Review Articles on . . .
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of
- About NEJM - The New England Journal of Medicine
With a 2023 Journal Impact Factor of 96 2, NEJM is a top-ranked, global, multi-specialty journal in the general medicine category [Source: 2023 Journal Impact Factor, Journal Citation Reports
- Xenotransplantation of a Porcine Kidney for End-Stage Kidney Disease
Xenotransplantation offers a potential solution to the organ shortage crisis A 62-year-old hemodialysis-dependent man with long-standing diabetes, advanced vasculopathy, and marked dialysis-access
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
In this phase 3b, open-label, controlled trial, adult participants with obesity but without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum tolerated dose of
- First-Line Camizestrant for Emerging - The New England Journal of Medicine
Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin-dependent kinase 4 and 6 (CDK4 6) inhibitor for advanced breast cancer
- Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
Tolebrutinib is an oral, brain-penetrant, and bioactive BTK inhibitor intended to target disease-associated microglia and B cells within the CNS in addition to their counterparts in the periphery
- Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal . . .
Tezepelumab is a human monoclonal antibody that specifically blocks TSLP from interacting with its heterodimeric receptor 21,22 Tezepelumab administered subcutaneously at a dose of 210 mg every 4
- Zongertinib in Previously Treated - The New England Journal of Medicine
In cohort 1, a total of 75 patients received zongertinib at a dose of 120 mg At the data cutoff (November 29, 2024), 71% of these patients (95% confidence interval [CI], 60 to 80; P<0 001 against
|
|
|